MedTrace Logo

Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency

NCT05829187 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-05-16

No results posted yet for this study

Summary

Currently, the first-line combination of artemisinin, piperaquine and prima-quine is quite effective in controlling malaria, however, the threat of spread of drug-resistant parasites has been reported. A study is conducted to assess the efficacy and safety extract of bitter melon (Momordica charantia/MC) regimens compared to the combination of dihydroartemisinin piperaquine primaquine (DHP+PQ) on the sexual and asexual stage of P. Falciparum uncomplicated in Sumba Barat Daya District, Indonesia

Conditions

  • Uncomplicated Plasmodium Falciparum

Interventions

DRUG

Dihydroartemisinin

dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days

DRUG

Piperaquine

piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days

DRUG

Primaquine

Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only

DRUG

Momordica Charantia Extract

Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days

Sponsors & Collaborators

  • Apt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati, M.Clin, Pharm, Ph.D

    collaborator UNKNOWN

  • Syamsudin Abdillah,Ph.D, Pharm D

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05829187 on ClinicalTrials.gov